ClinicalTrials.gg

Program

Optimized Background Regimen (OBR)

Its studies are led by Gilead Sciences.

Furthest: phase 3, since Oct 28, 20192 company-led studies, 2 open or runningNext primary completion: Mar 2027 (phase 2)

Who develops it

Each company that leads studies of it, as its sponsor page counts them.

CompanyStudies it leadsFurthest phaseFirst studyNext primary completion
Gilead Sciences22 open or runningphase 3since Oct 28, 2019Oct 28, 2019Mar 2027phase 2 · NCT06749054

History and what’s ahead

From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.

  1. Oct 28, 2019First study: phase 3 study in HIV-1-infectionFirst studyNCT04150068 · 72 enrolled · United States, Canada, Dominican Republic and more
  2. Dec 19, 2024Phase 2 study in HIV-1-infectionNCT06749054 · 12 planned · United States, South Africa

Ahead

  1. Mar 2027Primary completion: phase 2 study in HIV-1-infectionNCT06749054

TargetBeta

Not stated by its company or a source we have read. Most early programs say nothing of it.

Studies

All 2 led by companies developing it, newest first. Each opens its study page.

StudyPhaseStatusPrimary completionSize
NCT06749054HIV-1-infection · United States, South Africa2RecruitingMar 202712
NCT04150068HIV-1-infection · United States, Canada, Dominican Republic and more3Active, not recruitingOct 5, 202072

How it is read

Names in the registry

  • “Optimized Background Regimen (OBR)”, 2 entries

Conditions, from the studies’ own filings

    First seen by our ledger Nov 13, 2026.

    What this can’t show

    • Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
    • Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
    • Primary completion dates are the sponsors’ estimates and often move.
    • A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.